Jefferies Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jefferies Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,000	Closed	-$829K	–	1667
2022 Q2	$829K	Buy	+10,000	New	+$796K	0.01%	853
2021 Q4	–	Sell	-31,500	Closed	-$2.43M	–	1637
2021 Q3	$2.43M	Buy	31,500 +16,500	+110%	+$1.3M	0.02%	695
2021 Q2	$1.25M	Hold	15,000	–	–	0.01%	910
2021 Q1	$1.13M	Sell	15,000 -9,800	-40%	-$801K	0.01%	858
2020 Q4	$2.17M	Buy	24,800 +15,000	+153%	+$1.19M	0.02%	679
2020 Q3	$746K	Buy	9,800 +4,500	+85%	+$455K	0.01%	883
2020 Q2	$654	Hold	5,300	–	–	0.01%	852
2020 Q1	$448K	Buy	+5,300	New	+$457K	0.01%	1355
2019 Q4	–	Sell	-75,800	Closed	-$5.11M	–	2577
2019 Q3	$5.11M	Buy	75,800 +63,500	+516%	+$4.89M	0.04%	509
2019 Q2	$1.05M	Buy	12,300 +9,100	+284%	+$778K	0.01%	1265
2019 Q1	$284K	Sell	3,200 -14,000	-81%	-$1.3M	﹤0.01%	1821
2018 Q4	$1.47M	Buy	+17,200	New	+$1.64M	0.01%	983
2018 Q2	–	Sell	-50,000	Closed	-$4.05M	–	2316
2018 Q1	$4.05M	Hold	50,000	–	–	0.02%	553
2017 Q4	$4.46M	Buy	+50,000	New	+$4.35M	0.02%	608
2015 Q2	–	Sell	-35,000	Closed	-$4.36M	–	3298
2015 Q1	$4.36M	Buy	+35,000	New	+$3.71M	0.02%	465
2014 Q1	–	Sell	-16,800	Closed	-$1.18M	–	2036
2013 Q4	$1.18M	Buy	+16,800	New	+$1.14M	0.01%	762

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jefferies Group's BMRN Position: Q3 2022 in Review

Jefferies Group increased its BioMarin Pharmaceuticals (BMRN) stake by 795% in Q3 2022, buying an estimated $1.72M and bringing the position to 21,780 shares worth $1.85M. The position accounts for 0.02% of the portfolio, ranked #639.

Jefferies Group first reported a position in BMRN in Q2 2013 and has held it in 37 quarters since. The position peaked at $7.38M in Q3 2018. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Jefferies Group held 21,780 shares of BioMarin Pharmaceuticals worth $1.85M as of Q3 2022.
Jefferies Group bought 19,346 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $1.72M.
BioMarin Pharmaceuticals made up 0.02% of Jefferies Group's portfolio in Q3 2022, its #639 holding.
Jefferies Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
Jefferies Group's BioMarin Pharmaceuticals position peaked at $7.38M in Q3 2018.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.